Burkhard Möller

Color stability of dental composite resin materials for crown and bridge veneers

I. Eystein Ruyter, Krister Nilner, Burkhard Möller · Dental Materials · 1987 · 785 citations

Dentistry, Dental Materials Science, Restorative Dentistry +16

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn et al. · The Lancet Rheumatology · 2021 · 211 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

Axel Finckh, Adrian Ciurea, Laure Brulhart et al. · Arthritis & Rheumatism · 2007 · 210 citations

Life Sciences, Immunology, Internal Medicine +14

The -308 tumour necrosis factor-  gene polymorphism predicts therapeutic response to TNF -blockers in rheumatoid arthritis and spondyloarthritis patients

Michael Seitz, U. Wirthmüller, Burkhard Möller et al. · Lara D. Veeken · 2006 · 196 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Axel Finckh, Adrian Ciurea, Laure Brulhart et al. · Annals of the Rheumatic Diseases · 2009 · 171 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16